To evaluate upadacitinib as a treatment for recalcitrant vulvar lichen sclerosus and its efficacy.
Observational analysis of treatment outcomes
Evaluation of upadacitinib administration
Assessment of patient responses to therapy
Upadacitinib shows promise as an effective treatment option
Further studies required to confirm efficacy and understand limitations
Abstract
Upadacitinib may be an effective treatment option for recalcitrant vulvar LS. More robust studies are needed to fully evaluate the efficacy and limitations of JAK inhibitors in treating lichen sclerosus.